Related Experiment Video

Updated: May 11, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

LDL cholesterol in CKD--to treat or not to treat?

Ziad A Massy1, Dick de Zeeuw

  • 1Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest (UVSQ) University, Boulogne Billancourt/Paris, France. ziad.massy@apr.aphp.fr

Kidney International
|May 24, 2013
PubMed

Insights

Cholesterol management in chronic kidney disease (CKD) is complex. While statins benefit early CKD patients, optimal strategies for advanced stages remain unclear, requiring tailored approaches for cardiovascular risk reduction.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in chronic kidney disease (CKD) patients.
  • The relationship between serum lipids (total cholesterol, LDL cholesterol) and CVD risk differs in CKD compared to the general population.
  • Atherosclerosis accounts for approximately 30% of CVD events in CKD patients.

Purpose of the Study:

  • To review the current understanding of lipid management in CKD patients.
  • To discuss the evidence for cholesterol-lowering therapies in CKD.
  • To provide a practical plan for nephrologists managing atherosclerosis-related risk in CKD.

Main Methods:

  • Review of epidemiological data.
  • Analysis of intervention trial results (e.g., Study of Heart and Renal Protection).
  • Synthesis of meta-analysis findings on LDL cholesterol reduction and cardiovascular risk.

Main Results:

  • Cholesterol-lowering agents show proportional cardiovascular risk reduction in early CKD stages, similar to the general population.
  • The association between LDL cholesterol reduction and cardiovascular risk appears attenuated in end-stage kidney disease (ESKD).
  • Uncertainty exists regarding the optimal lipid management in ESKD patients.

Conclusions:

  • Cholesterol-lowering therapy is indicated in early CKD to mitigate atherosclerosis-related risk.
  • Further research and clinical guidance are needed for effective lipid management in ESKD.
  • A practical approach is proposed to aid nephrologists in managing cardiovascular risk with lipid-lowering therapies in CKD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...